Introduction

37
Milk proteins contain within their sequences encrypted peptides, known as bioactive 38 peptides, which may have potential to contribute to a wide range of bioactive properties in 39 vitro. While there is still much debate around the application of bioactive peptides to 40 modulate human health, there is a growing evidence in the literature reporting on their 41 positive outcomes during human intervention studies (Nongonierma & FitzGerald, 2015a) . 42
The role of milk protein-derived peptides as antidiabetic agents has attracted a lot of interest. 43
In particular, the inhibition of dipeptidyl peptidase IV (DPP-IV), a metabolic enzyme, with 44 various food protein-derived peptides has been extensively studied (Lacroix & Li-Chan, 45 2016). During the postprandial phase, DPP-IV is able to cleave incretins such as glucagon-46 like peptide 1 (GLP-1) and glucose inhibitory polypeptide (GIP). Incretin cleavage results in 47 their inactivation, which causes a loss in their insulinotropic activity (Juillerat-Jeanneret, 48 2014). Several DPP-IV inhibitory drugs, which belong to the class gliptins, are currently used 49 by type 2 diabetics as a means to regulate of postprandial serum glucose. While being 50 reported as minor, a number of side-effects, have been associated with the utilisation of 51 gliptins (Zhao et al., 2016) . In this context, the search for natural dietary compounds, which 52 to substrate (E:S) ratio) followed by RSM was employed to optimise DPP-IV inhibitory 86 peptide release during Neutrase 0.8L TM hydrolysis of MPI. In addition, the physicochemical 87 characteristics (degree of hydrolysis (DH), peptide profile and molecular mass distribution) 88 of the MPI hydrolysates were determined. The stability of the DPP-IV inhibitory properties 89 of MPI hydrolysates following incubation with digestive enzymes was assessed using an in 90 
In vitro SGID of intact and hydrolysed MPI 133
Both unhydrolysed MPI and H4 (one of the most potent DPP-IV inhibitory hydrolysate 134 generated within the experimental design) were subjected to SGID in vitro. This was carried 135 out as described by Walsh et al. (2004) . Briefly, samples were resuspended in distilled water 136 to 2% (w protein equivalent/w) for 30 min at 37°C and the pH was adjusted to 2.0 using 1 N 137
HCl. Hydrolysis with pepsin (E:S 2.5% (w/w); Biocatalysts, Cefn Coed, Wales, UK) was 138 carried out under pH regulation (2.0) with HCl (pH stat Titrando 843, Tiamo 1.4 Metrohm, 139
Dublin, Ireland) for 90 min at 37°C. Pepsin was then heat inactivated (90°C, 20 min). An 140 aliquot of the peptic hydrolysate (H4_pepsin or MPI_pepsin) was brought to pH 7.5 using 1 141 M NaOH and was subsequently hydrolysed with Corolase PP (E:S 1% (w/w); AB Enzymes, 142
Darmstadt, Germany) for 150 min at 37°C, pH 7.5 using a pH stat (Metrohm), yielding 143 H4_CorPP or MPI_CorPP. The reaction was terminated by thermal treatment (90°C, 20 min). 144
Samples were then freeze-dried and stored at -20°C until utilisation. 145
Determination of the DH 146
The DH of each hydrolysate (H1-H15) was determined in triplicate (n=3) using the TNBS 147 method outlined in Le Maux, Nongonierma, Barre & FitzGerald (2016 separation was carried out in isocratic mode at 21°C by injecting 20 µL of sample into a TSK 164 G2000 SW separating column (600×7.5 mm ID -Tosoh Bioscience, Tokyo, Japan) connected 165 to a TSKGEL SW guard column (75×7.5 mm ID -Tosoh Bioscience). The flow rate was set 166 at 0.5 mL min -1 for 60 min. The absorbance was monitored at 214 nm. Four molecular mass 167 bands within the chromatograms were defined as > 10, 10-5, 5-1 and < 1 kDa. 168
Peptide profiling of the hydrolysates using reverse-phase ultra-performance liquid 169 chromatography (RP-UPLC) 170
The peptide profile of the MPI hydrolysates was determined by RP-UPLC (UPLC Acquity -171 9 linear gradient: 0-0.28 min: 100% A; 0.28-60 min: 100-40% A. Absorbance was monitored at 179 214 nm. 180
DPP-IV inhibition assay 181
The DPP-IV inhibition assay was carried out as outlined by Nongonierma & FitzGerald 182 (2013a). Briefly, the freeze-dried samples were dispersed in HPLC grade water at 183 concentrations ranging from 2.7 × 10 -2 to 2.7 mg mL -1 (final concentration expressed in mg 184 protein equivalent mL -1 ). Diprotin A was used as a positive control at concentrations between 185 12.5 × 10 -2 and 12.5 µg mL -1 . Samples (25L) were mixed with the reaction substrate, Gly- was UniProtKB/Swiss-Prot (http://www.uniprot.org), taxa Bos taurus. The false discovery 227 rate (FDR), average local confidence (ALC) and MS/MS tolerance were set at 1, 60% and 0.1 228 Da, respectively. In addition, synthetic peptides (Phe-Phe, Phe-Leu, His-Leu, Leu-Leu, Ile-229
Leu, Leu-Ile, Ile-Ile, Val-Leu, Trp-Lys and Trp-Gln) were analysed using the same LC-230 MS/MS conditions in order to confirm the software identification (data not shown). All other 231 amino acid sequences generated by PEAKS Studio software were manually checked in order 232 to (1) verify that the peptide sequence existed in the main milk proteins and (2) control the 233 peptides fragmentation data (i.e., ion series continuity). (Table 1 ). In addition, these three hydrolysates displayed similar 255 molecular mass distribution profiles ( Fig. 1A) . 256
The DPP-IV IC 50 values determined for the hydrolysates (H1-H15) generated within the DOE 257 are reported in Table 1 . These varied between 0.60 ± 0.06 (H4) and 2.14 ± 0.21 mg mL -1 258 (H14). Hydrolysates generated at temperatures  50C generally displayed the lowest DPP-259 IV IC 50 values. For the other parameters (time and E:S), no clear trend could be seen. 260
Along with differences in their bioactive properties, dissimilarities in the physicochemical 261
properties of the hydrolysates were also seen. Their DH values ranged from 3.4 ± 0.6 (H11) 262 to 11.8 ± 0.7 (H4) or 11.8 ± 1.1% (H8A, Table 1 ). Differences in the molecular mass 263 distribution ( Fig. 1A ) and peptide profiles (data not shown) were also evident. All 264 hydrolysates still contained some intact proteins (material > 10 kDa), in particular 265 hydrolysates H11-H15 which were among the less hydrolysed samples. 266
Effect of the experimental design parameters on the DPP-IV inhibitory properties 267 of the MPI hydrolysates 268
A MLR was used to correlate the parameters of the DOE to the DPP-IV IC 50 values of the 269 resultant hydrolysate ( Table 2 ). The complete model was statistically significant with a p 270 value of 0.000905 and an R 2 of 0.95. However, the p value (< 0.05) for the lack of fit 271 indicated that the model did not fit well with the experimental data. For this reason, the most 272 significant parameters (T and t), their binary interactions (T 2 and t 2 ) and the t×E:S interaction 273 were taken into account to build the simplified model. 274
In the simplified model, a significant effect (p < 0.05) of T, t, T 2 , t 2 and t×E:S was also found 275 (Table 2 ). The p value (> 0.05) for the lack of fit indicated that the simplified model better 276 fitted the experimental data. For the main parameters of the DOE, the highest coefficient was 277 that of temperature (0.34, Table 2 ). Its positive value indicated that a decrease in temperature 278 would yield a decrease in the DPP-IV IC 50 value (more potent DPP-IV inhibitory 279 hydrolysate). This effect of temperature decrease in lowering the DPP-IV IC 50 value could be 280 visualised on the RSM curves ( Fig. 1B and 1D ). The negative value for the coefficient 281 associated with time (-0.13, Table 2 ) indicated a reduction in DPP-IV IC 50 value as 282 incubation time increased. However, the effect of time on DPP-IV IC 50 value is less than that 283 of the temperature ( Fig. 1B and 1C ). The significance of the binary interactions T 2 and t 2 284 suggests the existence of an optimum temperature and time for the generation of a DPP-IV 285 inhibitory hydrolysate within the boundaries of the DOE. In agreement with the lack of 286 statistical significance for the E:S (p > 0.05, Table 2 ), this parameter, minimally modified the 287 DPP-IV IC 50 value ( Fig. 1C and 1D ). 288
Optimisation of the release of DPP-IV inhibitory peptides during enzymatic 289 hydrolysis of MPI 290
The RSM allowed prediction of the optimum temperature, time and E:S yielding the most 291 potent DPP-IV inhibitory hydrolysate within the boundaries of the DOE. It was predicted that 292 an hydrolysate generated at 46 (-0.4)C, 240 (+1) min and 0.5% (-1) E:S would yield the 293 lowest DPP-IV IC 50 value, which was projected to be 0.43 mg mL -1 . The observed DPP-IV 294 H16C) are reported in Table 1 . These three hydrolysates yielded similar (p > 0.05) DPP-IV 296 IC 50 values, with an average of 0.60  0.07 mg mL -1 . A one-sample Student test was 297 conducted to compare the experimental to the predicted DPP-IV IC 50 value. Although the 298 DPP-IV IC 50 values predicted and experimentally determined were of the same order, 299 statistically significant differences (p > 0.05) were seen between both values. 300
Stability of DPP-IV inhibitory peptides to gastrointestinal enzymes 301
The stability of the DPP-IV inhibitory hydrolysates to digestive enzymes was studied using 302 an in vitro SGID protocol. Elution of peptide peaks differed in the RP-UPLC profiles of H4 303 and H4_CorPP, indicated peptide degradation following SGID ( Fig. 2A and 2B ). There was 304 no significant difference in the DPP-IV IC 50 values of H4, before and after the two steps of 305 the SGID process (pepsin followed by Corolase PP digestion, p > 0.05, Table 1 ). 306
Intact MPI did not inhibit DPP-IV (IC 50 > 2.7 mg mL -1 ). Following pepsin digestion, the 307 DPP-IV IC 50 value was 2.34 ± 0.28 mg mL -1 . A significant increase in DPP-IV inhibitory 308 potency (IC 50 = 0.65 ± 0.06 mg mL -1 , p < 0.05) was observed following pepsin and Corolase 309 PP digestion of MPI (MPI_CorPP). 310
Interestingly, there was no significant difference between the DPP-IV IC 50 values of H4, 311
H4_pepsin, H4_CorPP and MPI_CorPP (p > 0.05, Table 1 ). However, large differences in 312 the peptide profile of these samples were seen ( Fig. 2A-C) . 313
Identification of peptides within MPI hydrolysates 314
Previously identified DPP-IV inhibitory peptides were found within all four samples (H4, 315 H16, H4_CorPP and MPI_CorPP) analysed by LC-MS/MS (Table 3) Trp-Lys (lactoferrin -LF (f268-269)) and Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-319
Leu (-Lg (f46-57)), with previously reported DPP-IV IC 50 values of 74, 41 and 57 µM, 320 respectively. MPI_CorPP contained a particularly potent DPP-IV inhibitor, Val-Pro-Leu ( s1 -321 CN (f167-169)), also known as Diprotin B, displaying a DPP-IV IC 50 value of 16 µM. 322
Interestingly, Val-Leu/Val-Ile was found in all four samples analysed (Table 3) . Eight DPP-323 IV inhibitory peptides were common between H4 and H16, 6 were common between H4 and 324
H4_CorPP and 9 were common between H4_CorPP and MPI_CorPP. , were also found in the peptides identified within H4 (Table 4) . 367
Numerous peptides were common between H4 and H4_CorPP, while others were only 368 present in one of the hydrolysates. This was the case for Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-369
Leu-Glu-Ile-Leu, which was further degraded during SGID into shorter fragments such as 370
Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu (-Lg (f46-54)) and Leu-Lys-Pro-Thr-Pro-Glu-Gly-371
Asp-Leu-Glu (-Lg (f46-55)) which still displayed high DPP-IV inhibitory properties (DPP-372 IV IC 50 values of 45 and 42 µM, respectively (Lacroix & Li-Chan, 2014)). There is a need to 373 specifically quantify DPP-IV inhibitory peptides within H4 and H4_CorPP in order to better 374 understand the stability of peptides to SGID. However, this was outside the scope of the 375 present study. 376 While MPI_CorPP and H4_CorPP had a similar DPP-IV IC 50 value, their peptide 377 composition was quite different (Table 3) Asn-Gln-Phe-Leu-Pro-Tyr-Pro-Tyr is shown in Supplementary Fig. S1 . In order to assess if 383 there is a benefit to prehydrolyse MPI prior to its ingestion, in vivo studies need to be 384 performed to better understand the stability, bioavailability and efficacy of the peptides 385 released from H4 and MPI during gastrointestinal digestion. 386
The LC-MS/MS results, showing previously reported DPP-IV inhibitory peptides (Table 3) LPQNIPPL from gouda-type cheese and its effect on plasma glucose in rats. 535 Table 3 . Peptides identified by liquid chromatography tandem mass spectrometry (LC-MS/MS) within H4 before and after (H4_CorPP) simulated 580 gastrointestinal digestion (SGID), the SGID of milk protein isolate (MPI_CorPP) and H16, which have previously been reported in the literature for their 581 dipeptidyl peptidase IV (DPP-IV) inhibitory properties. 582 Peptide sequence §  Table 4 . Peptide sequences arising from -casein (-CN) identified within H4, which display features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides 588 (Trp (W 1 ), , Ile (I 1 ), Leu (L 1 ) or Phe (F 1 ) at the N-terminus and/or Pro (P 2 )/Ala (A 2 ) at position 2 and/or Pro at the C-terminus (P-term) 
